Key result
Administration of small-dose dexamethasone to an extremely low birth weight preterm infant resulted in acute, transient hypertrophic cardiomyopathy and cardiogenic shock.
Why the study?
Steroid-induced HCM in preterm neonates is typically insidious and transient, with little known about the adverse effects of small-dose steroids causing acute cardiac decompensation.
Does small-dose dexamethasone cause acute hypertrophic cardiomyopathy and cardiogenic shock in extremely low birth weight preterm infants?
Case Report (n=1)
No
Does small-dose dexamethasone cause acute hypertrophic cardiomyopathy and cardiogenic shock in extremely low birth weight preterm infants?
Small doses of dexamethasone used in extremely low birth weight infants can cause acute, transient hypertrophic cardiomyopathy and cardiogenic shock.
Answers are grounded in this paper and cite their sources.
May signal acute cardiac risk from dexamethasone in ELBW infants; hypothesis-generating and should not yet change practice.
This case report describes an extremely low birth weight infant, born at 26-week gestational age, who developed hypertrophic cardiomyopathy (HCM) and cardiogenic shock a few hours after administration of a small dose of dexamethasone. Although cases of steroid-induced cardiomyopathy in preterm neonates are known in literature, their adverse effects are insidious and are transient in occurrence. This is the first report of HCM and cardiogenic shock occurring acutely after administration of small-dose dexamethasone. This neonate received small-dose dexamethasone initially to prevent reintubation, and again to facilitate successful extubation. Both occurrences were associated with acute cardiac decompensation with reduction in ejection fraction within hours of administration. Cardiac function subsequently improved with discontinuation of drug and use of inotropic pharmacotherapy. Studies outlined in this report show that steroid-induced HCM is known and not isolated to dexamethasone alone; however, little is known on the adverse effect of small-dose steroid in resulting acute cardiac decompensation. This case is of educational value in clinical practice by highlighting the potential adverse effects even at the smaller doses of dexamethasone currently recommended in extremely low birth weight infants.
No takes yet. Share an insight, caveat, or question.
Luedtke et al. (2022) conducted a case report in Hypertrophic cardiomyopathy and cardiogenic shock (n=1). Dexamethasone was evaluated on Development of hypertrophic cardiomyopathy and cardiogenic shock. Administration of small-dose dexamethasone to an extremely low birth weight preterm infant resulted in acute, transient hypertrophic cardiomyopathy and cardiogenic shock.
Synapse has enriched 10 related papers. Consider them for comparative context: